# A Prospective Study Evaluating Seroprevalence and Seroconversion of Antibodies Against Adeno-associated Virus (AAV)

> **NCT05580692** · NA · TERMINATED · sponsor: **BioMarin Pharmaceutical** · enrollment: 321 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT05580692
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-03-14
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 321 (ACTUAL)
- **Why stopped:** Sponsor decision to terminate; sufficient sample size for statistical analysis has been achieved.
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05580692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05580692, "A Prospective Study Evaluating Seroprevalence and Seroconversion of Antibodies Against Adeno-associated Virus (AAV)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05580692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*